Commentary: Alternative safe, effective and cost-efficient dosing for eptifibatide in low-risk patients.
Helmy
Tarek
T
Emory University, Atlanta, Georgia, USA. tarek.helmy@UC.edu
Effat
Mohamed
M
D003324:Coronary Artery Disease / Q000628:therapy*; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D000077542:Eptifibatide; D006801:Humans; D010455:Peptides / Q000191:economics / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000191:economics / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D015607:Stents; D016896:Treatment Outcome
D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077542:Eptifibatide